· The enhanced delivery mechanism facilitates the drug's optimal deposition in the small airways, thereby augmenting its therapeutic efficacy and minimizing potential adverse effects.

· With a distinctive product appearance, the atomization performance and the aerodynamic basis of our device are proved to be equivalent to the novel product, allowing for replacement of the novel device (Symbicort® Turbuhaler®).

· Inspiratory resistance range 0.03 to 0.05（kPa·s/L）